Results 51 to 60 of about 15,828 (290)

Soluble CD40 ligand in acute coronary syndromes [PDF]

, 2003
BACKGROUND: CD40 ligand is expressed on platelets and released from them on activation. We investigated the predictive value of soluble CD40 ligand as a marker for clinical outcome and the therapeutic effect of glycoprotein IIb/IIIa receptor inhibition ...
Boersma, H. (Eric), Brand, M.J.B.M. (Marcel) van den, Dimmeler, S. (Stefanie), Hamm, C.W. (Christian), Heeschen, C. (Christopher), Simoons, M.L. (Maarten), Zeiher, A.M. (Andreas)   +6 more
core   +1 more source

Efficacy of Combination Treatment with Intracoronary Abciximab and Aspiration Thrombectomy on Myocardial Perfusion in Patients with ST-Segment Elevation Myocardial Infarction Undergoing Primary Coronary Stenting

Yonsei medical journal, 2014
Purpose We aimed to investigate whether combination therapy using intracoronary (IC) abciximab and aspiration thrombectomy (AT) enhances myocardial perfusion compared to each treatment alone in patients with ST-elevation myocardial infarction (STEMI ...
S. Ahn, Seung-Hwan Lee, Ji Hyun Lee, Jun-Won Lee, Y. Youn, Min-Soo Ahn, J. Kim, B. Yoo, Junghan Yoon, K. Choe, S. Tahk   +10 more
semanticscholar   +1 more source

Safety of Glycoprotein IIb-IIIa Inhibitors Used in Stroke-Related Treatment: A Systematic Review and Meta-Analysis

Clinical and Applied Thrombosis/Hemostasis, 2020
Background: Endovascular therapy and intravenous thrombolysis with recombinant tissue plasminogen activator are the 2 most recommended treatments for acute ischemic stroke (AIS). Glycoprotein (GP) IIb-IIIa inhibitors are short-acting selective reversible
Xiaolin Zhu MD, Genmao Cao MD
doaj   +1 more source

Evidence for Prevention of Death and Myocardial Infarction With Platelet Membrane Glycoprotein IIb/IIIa Receptor Blockade by Abciximab (c7E3 Fab) Among Patients With Unstable Angina Undergoing Percutaneous Coronary Revascularization fn1fn1This study was supported by Centocor, Inc., Malvern, Pennsylvania. [PDF]

, 1997
Objectives. We sought to evaluate whether patients with unstable angina undergoing coronary intervention derive particular clinical benefit from potent platelet inhibition.Background.
Aguirre, Frank V., Anderson, Keaven M., Califf, Robert M., Harrington, Robert A., Kleiman, Neal S., Lincoff, A.Michael, Topol, Eric J., Weisman, Harlan F.   +7 more
core   +1 more source

The FRED‐X Flow Diverter—An Australian Experience

Journal of Medical Imaging and Radiation Oncology, Volume 69, Issue 4, Page 484-490, June 2025.
ABSTRACT Background The FRED X flow diverter features antithrombotic surface treatment to reduce thrombogenicity. This study evaluated the safety and efficacy of FRED X in treating intracranial aneurysms in the Australian setting. Methods Clinical, procedural and imaging data were retrospectively reviewed for a consecutive series of patients at a ...
Peter Shuangyue Tan, Charles Li, Cameron Williams, Winston Chong, Carlos Chung, Conor Houlihan, Anoop Madan   +6 more
wiley   +1 more source

Reduction of recurrent ischemia with abciximab during continuous ECG-ischemia monitoring in patients with unstable angina refractory to standard treatment (CAPTURE) [PDF]

, 1998
BACKGROUND: In the CAPTURE (c7E3 Fab Anti Platelet Therapy in Unstable REfractory angina) trial, 1265 patients with refractory unstable angina were treated with abciximab or placebo, in addition to standard treatment from 16 to 24 hours
Klootwijk, A.P.J. (Peter), Lenderink, T. (Timo), Meij, S. (Simon), Melkert, R. (Rein), Simoons, M.L. (Maarten)   +4 more
core   +2 more sources

Hypercoagulability identified in dogs with chronic enteropathy using a point‐of‐care viscoelastic assay

Journal of Small Animal Practice, Volume 66, Issue 6, Page 365-371, June 2025.
Objectives Thromboelastography (TEG) using the TEG 6s, a point‐of‐care viscoelastic assay, was prospectively evaluated in dogs with chronic enteropathy (CE). Additionally, the study determined whether disease activity, assessed using the Canine Chronic Enteropathy Clinical Activity Index (CCECAI), correlated with TEG 6s parameters.
S. I. Barth, S. M. DeMonaco, B. J. Conner, A. R. Wilkinson   +3 more
wiley   +1 more source

Estudo experimental do uso de um antagonista do receptor da glicoproteína IIb/IIIa das placentas na prevenção de tromboses em microanastomoses vasculares An experimental study on the use of an antagonist of the platelet glycoprotein IIb/IIIa receptor in the prevention of thrombosis in vascular microanastomoses

Acta Ortopédica Brasileira, 2000
O autor comparou, experimentalmente, a eficácia da droga abciximab, um antagonista do receptor da glicoproteína IIb/IIIa das plaquetas, na prevenção da trombose nas microanastomoses arteriais em ratos Wistar.
Márcio Issamu Oide
doaj   +1 more source

CAN3: BASELINE COST OF ILLNESS OF PARKINSON'S DISEASE IN A LARGE HEALTHCARE PLAN [PDF]

, 2000
We present a mixed finite element formulation for the spatial discretization in dynamic analysis of non-isothermal variably saturated porous media using different order of approximating functions for solid displacements and fluid pressures/temperature ...
Cao, Toan Duc, Sanavia, Lorenzo, Schrefler, B. A., Wang, Yongqi   +3 more
core   +1 more source

Antithrombotic use in retinal artery occlusion: A narrative review

The Kaohsiung Journal of Medical Sciences, Volume 41, Issue 4, April 2025.
Abstract Retinal artery occlusion (RAO) is a critical ophthalmic emergency with a high risk of significant visual impairment. While traditional treatment aims to promptly restore blood flow to the retina, recent research has investigated the potential benefits of anticoagulation therapy for managing this condition. This paper reviews current literature
Wan‐Yu Liu, Yun‐Hsin Tang, Yi‐Hsing Chen   +2 more
wiley   +1 more source